pGreenFire1-mCMV Negative Control Lentivector

Run your pGreenFire projects with confidence with the addition of this negative control that drives copGFP and luciferase with a minimal CMV promoter

Products

Catalog Number Description Size Price Quantity Add to Cart
TR010PA-1 pGreenFire1-mCMV Plasmid (pTRH1 mCMV dscGFP T2A Fluc, negative control) 10 µg $594
- +
TR010VA-1 pGreenFire1-mCMV Virus (pTRH1 mCMV dscGFP T2A Fluc) >2 x 10^6 IFUs $747
- +

Overview

Overview

Supporting your studies with ready-to-go controls

No need to make a negative control for your pGreenFire projects—SBI’s already built one for you. With the pGreenFire1-mCMV Negative Control Lentivector, the GreenFire cassette is driven by a minimal CMV promoter with dscGFP (destabilized copGFP, 2-hour half-life) and luciferase co-expression mediated by a T2A element. The minimal CMV promoter delivers negligible expression, and this configuration provides a control for background levels of dscGFP and luciferase expression in the absence of enhancer elements, such as the ones used in our Signal Transduction Pathway Reporters/Transcriptional Response Element Reporters.

pGreenFire1-mCMV Negative Control Lentivector The pGreenFire1-mCMV vector is also available with constitutively expressed markers to simplify cell line construction—EF1α-neo (Cat.# TR010PA-N) and EF1α-puro (Cat.# TR010PA-P). All versions of this lentivector are available as lentivector or pre-packaged virus.

How It Works

Supporting Data

Supporting Data

See our transcriptional response element reporters in action

Monitor oncogenic pathway reporters

Track and measure the activity of oncogenic signal transduction pathways in live cellsTrack and measure the activity of oncogenic signal transduction pathways in live cells

Develop target gene-specific LXR agonists that could regulate reverse cholesterol transport without increasing lipogenesisDevelop target gene-specific LXR agonists that could regulate reverse cholesterol transport without increasing lipogenesisDevelop target gene-specific LXR agonists that could regulate reverse cholesterol transport without increasing lipogenesis

General pGreenFire data examplesSee SBI’s pGreenFire1 reporters in action

Monitoring NF-κB transactivationSee SBI’s pGreenFire1 reporters in actionSee SBI’s pGreenFire1 reporters in action

FAQs

Resources

Citations

  • Gampala, S, et al. (2024) New Ref-1/APE1 targeted inhibitors demonstrating improved potency for clinical applications in multiple cancer types. Pharmacological Research. 2024;:107092. Link: Pharmacological Research
  • Liu, YN, et al. (2024) Immunosuppressive role of BDNF in therapy-induced neuroendocrine prostate cancer. Molecular oncology. 2024;. PM ID: 38381121
  • Ishino, T, et al. (2023) Somatic mutations can induce a noninflamed tumour microenvironment via their original gene functions, despite deriving neoantigens. British journal of cancer. 2023;. PM ID: 36732592
  • Pandi, K, et al. (2023) Porphyromonas gingivalis induction of TLR2 association with Vinculin enables PI3K activation and immune evasion. PLoS pathogens. 2023; 19(4):e1011284. PM ID: 37023213
  • Ramachandran, M, et al. (2023) Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma. Cancer cell. 2023;. PM ID: 37172581
  • Wen, YC, et al. (2023) CHRM4/AKT/MYCN upregulates interferon alpha-17 in the tumor microenvironment to promote neuroendocrine differentiation of prostate cancer. Cell death & disease. 2023; 14(5):304. PM ID: 37142586
  • Li, X, et al. (2023) Rosmarinic acid ameliorates autoimmune responses through suppression of intracellular nucleic acid-mediated type I interferon expression. Biochemical and Biophysical Research Communications. 2023;. Link: Biochemical and Biophysical Research Communications
  • Ibrahim, L, et al. (2023) Succinylation of a KEAP1 sensor lysine promotes NRF2 activation. bioRxiv : the preprint server for biology. 2023;. PM ID: 37215033
  • Park, CS, et al. (2023) Stromal-induced epithelial-mesenchymal transition induces targetable drug resistance in acute lymphoblastic leukemia. Cell reports. 2023; 42(7):112804. PM ID: 37453060
  • Ouyang, W, et al. (2023) Development of a New Cell-Based AP-1 Gene Reporter Potency Assay for Anti-Anthrax Toxin Therapeutics. Toxins. 2023; 15(9):528. Link: Toxins
  • Zhao, G, et al. (2023) Base editing of the mutated TERT promoter inhibits liver tumor growth. Hepatology (Baltimore, Md.). 2023;. PM ID: 38016019
  • You, S & Bollong, MJ. (2023) A high throughput screen for pharmacological inhibitors of the carbohydrate response element. Scientific data. 2023; 10(1):676. PM ID: 37794069
  • Melo, CL. (2023) LUMINALABREASTCANCER: INSIGHTS INTOCELLCYCLEREGULATIONAND ESTROGENSIGNALING. Thesis. 2023;. Link: Thesis
  • Labanieh, L, et al. (2022) Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. Cell. 2022;. PM ID: 35483375
  • Teng, CT, et al. (2022) SUPPLEMENTARY MATERIAL: Development of novel cell lines for high throughput screening to detect estrogen-related receptor alpha modulators. slas-discovery.org. 2022;. Link: slas-discovery.org
  • Dane, EL, et al. (2022) STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity. Nature materials. 2022; 21(6):710-720. PM ID: 35606429
  • Liu, Y, et al. (2022) MCTP1 promotes SNAI1-driven neuroendocrine differentiation and epithelial-to- mesenchymal transition of prostate cancer enhancement by ZBTB46/FOXA2/HIF1A. Research Square. 2022;. Link: Research Square
  • Deng, Z, Lyu, W & Zhang, G. (2022) High-Throughput Identification of Epigenetic Compounds to Enhance Chicken Host Defense Peptide Gene Expression. Antibiotics (Basel, Switzerland). 2022; 11(7). PM ID: 35884187
  • Chang, WM, et al. (2022) The aberrant cancer metabolic gene carbohydrate sulfotransferase 11 promotes non-small cell lung cancer cell metastasis via dysregulation of ceruloplasmin and intracellular iron balance. Translational oncology. 2022; 25:101508. PM ID: 35985204
  • Chen, C, et al. (2022) ATF4-dependent fructolysis fuels growth of glioblastoma multiforme. Nature communications. 2022; 13(1):6108. PM ID: 36245009

Products

Catalog Number Description Size Price Quantity Add to Cart
TR010PA-1 pGreenFire1-mCMV Plasmid (pTRH1 mCMV dscGFP T2A Fluc, negative control) 10 µg $594
- +
TR010VA-1 pGreenFire1-mCMV Virus (pTRH1 mCMV dscGFP T2A Fluc) >2 x 10^6 IFUs $747
- +

Overview

Overview

Supporting your studies with ready-to-go controls

No need to make a negative control for your pGreenFire projects—SBI’s already built one for you. With the pGreenFire1-mCMV Negative Control Lentivector, the GreenFire cassette is driven by a minimal CMV promoter with dscGFP (destabilized copGFP, 2-hour half-life) and luciferase co-expression mediated by a T2A element. The minimal CMV promoter delivers negligible expression, and this configuration provides a control for background levels of dscGFP and luciferase expression in the absence of enhancer elements, such as the ones used in our Signal Transduction Pathway Reporters/Transcriptional Response Element Reporters.

pGreenFire1-mCMV Negative Control Lentivector The pGreenFire1-mCMV vector is also available with constitutively expressed markers to simplify cell line construction—EF1α-neo (Cat.# TR010PA-N) and EF1α-puro (Cat.# TR010PA-P). All versions of this lentivector are available as lentivector or pre-packaged virus.

How It Works

Supporting Data

Supporting Data

See our transcriptional response element reporters in action

Monitor oncogenic pathway reporters

Track and measure the activity of oncogenic signal transduction pathways in live cellsTrack and measure the activity of oncogenic signal transduction pathways in live cells

Develop target gene-specific LXR agonists that could regulate reverse cholesterol transport without increasing lipogenesisDevelop target gene-specific LXR agonists that could regulate reverse cholesterol transport without increasing lipogenesisDevelop target gene-specific LXR agonists that could regulate reverse cholesterol transport without increasing lipogenesis

General pGreenFire data examplesSee SBI’s pGreenFire1 reporters in action

Monitoring NF-κB transactivationSee SBI’s pGreenFire1 reporters in actionSee SBI’s pGreenFire1 reporters in action

FAQs

Citations

  • Gampala, S, et al. (2024) New Ref-1/APE1 targeted inhibitors demonstrating improved potency for clinical applications in multiple cancer types. Pharmacological Research. 2024;:107092. Link: Pharmacological Research
  • Liu, YN, et al. (2024) Immunosuppressive role of BDNF in therapy-induced neuroendocrine prostate cancer. Molecular oncology. 2024;. PM ID: 38381121
  • Ishino, T, et al. (2023) Somatic mutations can induce a noninflamed tumour microenvironment via their original gene functions, despite deriving neoantigens. British journal of cancer. 2023;. PM ID: 36732592
  • Pandi, K, et al. (2023) Porphyromonas gingivalis induction of TLR2 association with Vinculin enables PI3K activation and immune evasion. PLoS pathogens. 2023; 19(4):e1011284. PM ID: 37023213
  • Ramachandran, M, et al. (2023) Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma. Cancer cell. 2023;. PM ID: 37172581
  • Wen, YC, et al. (2023) CHRM4/AKT/MYCN upregulates interferon alpha-17 in the tumor microenvironment to promote neuroendocrine differentiation of prostate cancer. Cell death & disease. 2023; 14(5):304. PM ID: 37142586
  • Li, X, et al. (2023) Rosmarinic acid ameliorates autoimmune responses through suppression of intracellular nucleic acid-mediated type I interferon expression. Biochemical and Biophysical Research Communications. 2023;. Link: Biochemical and Biophysical Research Communications
  • Ibrahim, L, et al. (2023) Succinylation of a KEAP1 sensor lysine promotes NRF2 activation. bioRxiv : the preprint server for biology. 2023;. PM ID: 37215033
  • Park, CS, et al. (2023) Stromal-induced epithelial-mesenchymal transition induces targetable drug resistance in acute lymphoblastic leukemia. Cell reports. 2023; 42(7):112804. PM ID: 37453060
  • Ouyang, W, et al. (2023) Development of a New Cell-Based AP-1 Gene Reporter Potency Assay for Anti-Anthrax Toxin Therapeutics. Toxins. 2023; 15(9):528. Link: Toxins
  • Zhao, G, et al. (2023) Base editing of the mutated TERT promoter inhibits liver tumor growth. Hepatology (Baltimore, Md.). 2023;. PM ID: 38016019
  • You, S & Bollong, MJ. (2023) A high throughput screen for pharmacological inhibitors of the carbohydrate response element. Scientific data. 2023; 10(1):676. PM ID: 37794069
  • Melo, CL. (2023) LUMINALABREASTCANCER: INSIGHTS INTOCELLCYCLEREGULATIONAND ESTROGENSIGNALING. Thesis. 2023;. Link: Thesis
  • Labanieh, L, et al. (2022) Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. Cell. 2022;. PM ID: 35483375
  • Teng, CT, et al. (2022) SUPPLEMENTARY MATERIAL: Development of novel cell lines for high throughput screening to detect estrogen-related receptor alpha modulators. slas-discovery.org. 2022;. Link: slas-discovery.org
  • Dane, EL, et al. (2022) STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity. Nature materials. 2022; 21(6):710-720. PM ID: 35606429
  • Liu, Y, et al. (2022) MCTP1 promotes SNAI1-driven neuroendocrine differentiation and epithelial-to- mesenchymal transition of prostate cancer enhancement by ZBTB46/FOXA2/HIF1A. Research Square. 2022;. Link: Research Square
  • Deng, Z, Lyu, W & Zhang, G. (2022) High-Throughput Identification of Epigenetic Compounds to Enhance Chicken Host Defense Peptide Gene Expression. Antibiotics (Basel, Switzerland). 2022; 11(7). PM ID: 35884187
  • Chang, WM, et al. (2022) The aberrant cancer metabolic gene carbohydrate sulfotransferase 11 promotes non-small cell lung cancer cell metastasis via dysregulation of ceruloplasmin and intracellular iron balance. Translational oncology. 2022; 25:101508. PM ID: 35985204
  • Chen, C, et al. (2022) ATF4-dependent fructolysis fuels growth of glioblastoma multiforme. Nature communications. 2022; 13(1):6108. PM ID: 36245009